These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 30446569)
1. IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4 Jin Z; Lei L; Lin D; Liu Y; Song Y; Gong H; Zhu Y; Mei Y; Hu B; Wu Y; Zhang G; Liu H J Immunol; 2018 Dec; 201(12):3770-3779. PubMed ID: 30446569 [TBL] [Abstract][Full Text] [Related]
2. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200 [TBL] [Abstract][Full Text] [Related]
3. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Homma S; Komita H; Sagawa Y; Ohno T; Toda G Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514 [TBL] [Abstract][Full Text] [Related]
4. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713 [TBL] [Abstract][Full Text] [Related]
5. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581 [TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390 [TBL] [Abstract][Full Text] [Related]
7. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
8. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model. Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503 [TBL] [Abstract][Full Text] [Related]
9. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366 [TBL] [Abstract][Full Text] [Related]
10. Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses. Wu X; Li Y; Song CB; Chen YL; Fu YJ; Jiang YJ; Ding HB; Shang H; Zhang ZN Front Immunol; 2018; 9():2850. PubMed ID: 30564243 [TBL] [Abstract][Full Text] [Related]
11. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
12. In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity. Cottagiri M; Nyandjo M; Stephens M; Mantilla JJ; Saito H; Mackay IR; Rose NR; Njoku DB Cell Mol Immunol; 2019 Aug; 16(8):706-717. PubMed ID: 30030493 [TBL] [Abstract][Full Text] [Related]
13. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224 [TBL] [Abstract][Full Text] [Related]
14. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells. Xiang J; Chen Z; Huang H; Moyana T Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525 [TBL] [Abstract][Full Text] [Related]
15. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071 [TBL] [Abstract][Full Text] [Related]